Nuvation Bio (NYSE:NUVB - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $21.00 target price on the stock. HC Wainwright's price target would suggest a potential upside of 442.78% from the company's previous close.
Several other brokerages have also recently weighed in on NUVB. Wedbush reaffirmed an "outperform" rating and set a $11.00 target price on shares of Nuvation Bio in a research note on Wednesday, September 16th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nuvation Bio in a research report on Thursday, October 15th. Royal Bank Of Canada cut their price target on shares of Nuvation Bio from $20.00 to $17.00 and set an "outperform" rating for the company in a report on Thursday, November 5th. Citizens Jmp reissued a "market outperform" rating and issued a $10.00 price target on shares of Nuvation Bio in a report on Wednesday, September 16th. Finally, Citigroup restated a "market outperform" rating on shares of Nuvation Bio in a research report on Monday, October 19th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $12.89.
Get Our Latest Stock Analysis on Nuvation Bio
Nuvation Bio Stock Down 3.0%
Shares of NUVB stock opened at $3.87 on Tuesday. Nuvation Bio has a 1 year low of $3.82 and a 1 year high of $9.75. The stock has a market cap of $1.37 billion, a PE ratio of -9.67 and a beta of 1.73. The business's fifty day moving average is $5.07 and its 200-day moving average is $5.33. The company has a debt-to-equity ratio of 1.23, a quick ratio of 7.30 and a current ratio of 7.45.
Nuvation Bio (NYSE:NUVB - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). The company had revenue of $44.95 million for the quarter, compared to the consensus estimate of $34.39 million. Nuvation Bio had a negative return on equity of 45.69% and a negative net margin of 67.38%. Equities analysts expect that Nuvation Bio will post -0.37 earnings per share for the current fiscal year.
Insider Activity
In other news, insider Gary Hattersley sold 100,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total transaction of $709,000.00. Following the completion of the sale, the insider owned 100,000 shares in the company, valued at approximately $709,000. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 30.11% of the company's stock.
Hedge Funds Weigh In On Nuvation Bio
A number of hedge funds have recently modified their holdings of NUVB. Renaissance Technologies LLC purchased a new stake in shares of Nuvation Bio during the first quarter valued at $2,399,000. Bank of New York Mellon Corp acquired a new position in shares of Nuvation Bio in the 2nd quarter valued at $3,804,000. NewEdge Advisors LLC boosted its position in shares of Nuvation Bio by 19.5% in the 2nd quarter. NewEdge Advisors LLC now owns 1,231,733 shares of the company's stock valued at $6,996,000 after purchasing an additional 200,621 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Nuvation Bio in the 2nd quarter worth about $625,000. Finally, Arrowstreet Capital Limited Partnership increased its stake in Nuvation Bio by 75.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,439,357 shares of the company's stock worth $6,175,000 after purchasing an additional 619,725 shares in the last quarter. 61.67% of the stock is currently owned by institutional investors and hedge funds.
Nuvation Bio Company Profile
(
Get Free Report)
Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nuvation Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.
While Nuvation Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.